Lyflex Oral Solution (Baclofen)
Baclofen is in a class of medications called skeletal muscle relaxants.
Baclofen is indicated for:
The relief of voluntary muscle spasticity resulting from disorders such as: multiple sclerosis, other spinal lesions, e.g. tumours of the spinal cord, syringomyelia, motor neurone disease, transverse myelitis, traumatic partial section of the cord.
In adults and children for the relief of spasticity of voluntary muscle arising from e.g. cerebrovascular accidents, cerebral palsy, meningitis, traumatic head injury.
Paediatric population
Baclofen is indicated in patients 0 to <18 years for the symptomatic treatment of spasticity of cerebral origin, especially where due to infantile cerebral palsy, as well as following cerebrovascular accidents or in the presence of neoplastic or degenerative brain disease.
Baclofen is also indicated for the symptomatic treatment of muscle spasms occurring in spinal cord diseases of infectious, degenerative, traumatic, neoplastic, or unknown origin such as multiple sclerosis, spastic spinal paralysis, amyotrophic lateral sclerosis, syringomyelia, transverse myelitis, traumatic paraplegia or paraparesis, and compression of the spinal cord.
Summary of Product Characteristics
Read this summary of product characteristics for further information about Baclofen Oral Solution. Click below to navigate to the EMC.
Patient Information Leaflet
Read this patient information leaflet about Baclofen Oral Solution, what it’s used for and possible side effects. Click below to navigate to the EMC.
Lyflex Oral Solution (Baclofen)
| Click here for Audio Version | |
| Flavour | Raspberry |
| Storage Conditions | Do not store above 25°C. Store in the original container. Do not refrigerate or freeze. |
| Sucrose Free | |
| Shelf Life (Closed Bottle/Open Bottle) | 2 years/56 days |
| PIP Code | 3086311 |
| EAN Code | 5016119000867 |
| Sodium Levels | Essentially sodium-free at doses less than 30ml . At maximum daily dose (100 ml) this medicine contains 77 mg of sodium |
| Ethanol Concentration | None |
Downloads
Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk
Adverse events should also be reported to Rosemont at 0113 244 1400 or pharmacovigilance@rosemontpharma.com.
Contact us
For further product information and pricing please use the form below and a member of the team will be in touch
Stay updated via our App
A new Rosemont Pharmaceuticals App for Healthcare Professionals is launching soon.
Related Products
